acarbose

Summary

Summary: An inhibitor of ALPHA-GLUCOSIDASES that retards the digestion and absorption of DIETARY CARBOHYDRATES in the SMALL INTESTINE.

Top Publications

  1. Vichayanrat A, Ploybutr S, Tunlakit M, Watanakejorn P. Efficacy and safety of voglibose in comparison with acarbose in type 2 diabetic patients. Diabetes Res Clin Pract. 2002;55:99-103 pubmed
    We performed a randomized crossover open comparative study to evaluate the efficacy and safety of voglibose and acarbose in 30 patients with type 2 diabetes who were not well controlled with diet therapy...
  2. Pan C, Gao Y, Chen J, Luo B, Fu Z, Lu J, et al. Efficacy of acarbose in Chinese subjects with impaired glucose tolerance. Diabetes Res Clin Pract. 2003;61:183-90 pubmed
    This multicentre, double-blind, placebo-controlled study investigated the efficacy of acarbose in Chinese individuals with impaired glucose tolerance (determined using a 75 g oral glucose tolerance test)...
  3. Rockser Y, Wehmeier U. The gac-gene cluster for the production of acarbose from Streptomyces glaucescens GLA.O: identification, isolation and characterization. J Biotechnol. 2009;140:114-23 pubmed publisher
    The C7N-cyclitol containing alpha-glucosidase inhibitor acarbose is commercially produced using developed strains of Actinoplanes and is used in the treatment of patients suffering from diabetes type II...
  4. Jian Z, Zhou B. Efficacy and safety of acarbose in the treatment of elderly patients with postprandial hypotension. Chin Med J (Engl). 2008;121:2054-9 pubmed
    ..We hypothesized that acarbose (alpha-glucosidase inhibitor), a hypoglycemic agent that decreases the rate of glucose absorption in the small ..
  5. Wagner H, Degerblad M, Thorell A, Nygren J, Stahle A, Kuhl J, et al. Combined treatment with exercise training and acarbose improves metabolic control and cardiovascular risk factor profile in subjects with mild type 2 diabetes. Diabetes Care. 2006;29:1471-7 pubmed
    The effect of exercise training and acarbose on glycemic control, insulin sensitivity, and phenotype was investigated in mild type 2 diabetes...
  6. Derosa G, Salvadeo S, D Angelo A, Ferrari I, Mereu R, Palumbo I, et al. Metabolic effect of repaglinide or acarbose when added to a double oral antidiabetic treatment with sulphonylureas and metformin: a double-blind, cross-over, clinical trial. Curr Med Res Opin. 2009;25:607-15 pubmed
    To compare the metabolic effects of acarbose and repaglinide in type 2 diabetic patients who are being treated with a sulphonylurea-metformin combination therapy...
  7. Zhu Q, Tong Y, Wu T, Li J, Tong N. Comparison of the hypoglycemic effect of acarbose monotherapy in patients with type 2 diabetes mellitus consuming an Eastern or Western diet: a systematic meta-analysis. Clin Ther. 2013;35:880-99 pubmed publisher
    Because of its mechanism of action, the starch content of a diet might alter the hypoglycemic effect of acarbose. We aimed to determine whether differences in this hypoglycemic effect existed between individuals consuming Eastern and ..
  8. Adisakwattana S, Charoenlertkul P, Yibchok anun S. alpha-Glucosidase inhibitory activity of cyanidin-3-galactoside and synergistic effect with acarbose. J Enzyme Inhib Med Chem. 2009;24:65-9 pubmed
    ..showed a synergistic inhibition on intestinal alpha-glucosidase (maltase and sucrase) when combined with acarbose. A kinetic analysis showed that cyanidin-3-galactoside gave a mixed type inhibition against intestinal sucrase...
  9. Moreira R, Moreira R, Machado N, Gonçalves T, Coutinho W. Post-prandial hypoglycemia after bariatric surgery: pharmacological treatment with verapamil and acarbose. Obes Surg. 2008;18:1618-21 pubmed publisher
    ..Because of the possibility of NIPHS, clinical treatment was initiated with verapamil and acarbose, leading to a significant reduction of hypoglycemic episodes and also their severity...

More Information

Publications62

  1. Hasegawa G, Kajiyama S, Tanaka T, Imai S, Kozai H, Fujinami A, et al. The alpha-glucosidase inhibitor acarbose reduces the net electronegative charge of low-density lipoprotein in patients with newly diagnosed type 2 diabetes. Clin Chim Acta. 2008;390:110-4 pubmed publisher
    ..The present study was conducted in order to compare the effects of acarbose and glimepiride treatment on serum lipoprotein profiles in patients with type 2 diabetes...
  2. Pan C. Reducing the risk of type 2 diabetes: early identification of high-risk individuals and treatment with acarbose. Curr Diabetes Rev. 2007;3:141-8 pubmed
    ..Lifestyle modification and some pharmacologic therapies, such as acarbose, have been shown to significantly reduce disease progression...
  3. Li C, Hung Y, Qamruddin K, Aziz M, Stein H, Schmidt B. International noninterventional study of acarbose treatment in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2011;92:57-64 pubmed publisher
    To obtain data on efficacy, safety and tolerability of acarbose monotherapy or combination therapy during daily-life treatment...
  4. Derosa G, Mereu R, D Angelo A, Salvadeo S, Ferrari I, Fogari E, et al. Effect of pioglitazone and acarbose on endothelial inflammation biomarkers during oral glucose tolerance test in diabetic patients treated with sulphonylureas and metformin. J Clin Pharm Ther. 2010;35:565-79 pubmed publisher
    ..To compare the effect of addition of pioglitazone and acarbose to sulphonylureas and metformin therapy on metabolic parameters and on markers of endothelial dysfunction and ..
  5. Li K, Zhou J, Wei S, Cheng X. An optimized industrial fermentation processes for acarbose production by Actinoplanes sp. A56. Bioresour Technol. 2012;118:580-3 pubmed publisher
    b>Acarbose, a competitive ?-glucosidase inhibitor, is clinically and widely used in the treatment of type II diabetes mellitus. In order to improve the industrial acarbose productivity by Actinoplanes sp...
  6. Hsieh C. Acarbose reduces the risk of pre-lunch hypoglycemia in elderly people with diabetes eating rice porridge for breakfast. Diabetes Res Clin Pract. 2010;89:e66-8 pubmed publisher
    ..and late hypoglycemia in elderly people with diabetes who eat rice porridge for breakfast, we administered 50mg acarbose to 30 elderly people with type 2 diabetes...
  7. Aoki K, Muraoka T, Ito Y, Togashi Y, Terauchi Y. Comparison of adverse gastrointestinal effects of acarbose and miglitol in healthy men: a crossover study. Intern Med. 2010;49:1085-7 pubmed
    ..There has been no direct investigation of the adverse effects with acarbose or miglitol, therefore we compared them in healthy subjects...
  8. Gentilcore D, Bryant B, Wishart J, Morris H, Horowitz M, Jones K. Acarbose attenuates the hypotensive response to sucrose and slows gastric emptying in the elderly. Am J Med. 2005;118:1289 pubmed
  9. Pan C, Yang W, Barona J, Niggli M, Mohideen P, Wang Y, et al. Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24-week, double-blind, randomized trial. Diabet Med. 2008;25:435-41 pubmed publisher
    ..and tolerability of the dipeptidyl peptidase-4 inhibitor, vildagliptin, with the alpha glucosidase inhibitor, acarbose, in drug-naive patients with Type 2 diabetes...
  10. Pistrosch F, Schaper F, Passauer J, Koehler C, Bornstein S, Hanefeld M. Effects of the alpha glucosidase inhibitor acarbose on endothelial function after a mixed meal in newly diagnosed type 2 diabetes. Horm Metab Res. 2009;41:104-8 pubmed publisher
    ..Recent trials demonstrated a reduction of cardiovascular events by treatment with alpha-glucosidase inhibitor acarbose - a drug which mainly reduces postprandial glucose excursions...
  11. Lin B, Wu H, Huang H, Juang J, Huarng J, Sison A, et al. Efficacy and tolerability of acarbose in Asian patients with type 2 diabetes inadequately controlled with diet and sulfonylureas. J Diabetes Complications. 2003;17:179-85 pubmed
    The objective of this study was to investigate the efficacy, tolerability, and safety of acarbose in the improvement of glycemic control in Asian patients with type 2 diabetes inadequately controlled by diet and sulfonylureas...
  12. Pan C, Landen H. Post-marketing surveillance of acarbose treatment in patients with type 2 diabetes mellitus and subjects with impaired glucose tolerance in China. Clin Drug Investig. 2007;27:397-405 pubmed
    ..9 weeks to assess the efficacy, safety and acceptance of acarbose in Chinese patients with type 2 diabetes mellitus and subjects with impaired glucose tolerance (IGT) in routine ..
  13. Shimazu T, Inami N, Satoh D, Kajiura T, Yamada K, Iwasaka T, et al. Effect of acarbose on platelet-derived microparticles, soluble selectins, and adiponectin in diabetic patients. J Thromb Thrombolysis. 2009;28:429-35 pubmed publisher
    ..b>Acarbose has been shown to have a beneficial effect on postprandial hyperglycemia in diabetic patients...
  14. Shibao C, Gamboa A, Diedrich A, Dossett C, Choi L, Farley G, et al. Acarbose, an alpha-glucosidase inhibitor, attenuates postprandial hypotension in autonomic failure. Hypertension. 2007;50:54-61 pubmed
    ..We hypothesized that acarbose, an alpha-glucosidase inhibitor that decreases glucose absorption in the small intestine, would attenuate ..
  15. Rosak C, Mertes G. Effects of acarbose on proinsulin and insulin secretion and their potential significance for the intermediary metabolism and cardiovascular system. Curr Diabetes Rev. 2009;5:157-64 pubmed
    The alpha-glucosidase inhibitor acarbose is administered to control blood glucose levels in type 2 diabetic patients and, in several countries, in those with impaired glucose tolerance...
  16. Schwientek P, Szczepanowski R, Ruckert C, Kalinowski J, Klein A, Selber K, et al. The complete genome sequence of the acarbose producer Actinoplanes sp. SE50/110. BMC Genomics. 2012;13:112 pubmed publisher
    Actinoplanes sp. SE50/110 is known as the wild type producer of the alpha-glucosidase inhibitor acarbose, a potent drug used worldwide in the treatment of type-2 diabetes mellitus...
  17. Hwu C, Ho L, Fuh M, Siu S, Sutanegara D, Piliang S, et al. Acarbose improves glycemic control in insulin-treated Asian type 2 diabetic patients: results from a multinational, placebo-controlled study. Diabetes Res Clin Pract. 2003;60:111-8 pubmed
    The purpose of the study was to determine the efficacy and tolerability of acarbose in Asian type 2 diabetic patients insufficiently controlled by insulin...
  18. Kelly R, Leemhuis H, Gätjen L, Dijkhuizen L. Evolution toward small molecule inhibitor resistance affects native enzyme function and stability, generating acarbose-insensitive cyclodextrin glucanotransferase variants. J Biol Chem. 2008;283:10727-34 pubmed publisher
    ..glucanotransferase (CGTase) enzyme toward insensitivity to the small molecule inhibitor of the protein, acarbose. Error-prone PCR mutagenesis was applied to search the sequence space of CGTase for acarbose-insensitive variants...
  19. Hanefeld M, Schaper F, Koehler C. Effect of acarbose on vascular disease in patients with abnormal glucose tolerance. Cardiovasc Drugs Ther. 2008;22:225-31 pubmed publisher
    ..b>Acarbose, a potent competitive inhibitor of alpha-glucosidases of the small intestine specifically reduces pp ..
  20. Siraj E. Is there a role for metformin or acarbose as a weight-loss agent in the absence of diabetes?. Cleve Clin J Med. 2003;70:702-4 pubmed
  21. Bavenholm P, Efendic S. Postprandial hyperglycaemia and vascular damage--the benefits of acarbose. Diab Vasc Dis Res. 2006;3:72-9 pubmed
    ..However, in the Study to Prevent Non-Insulin Dependent Diabetes Mellitus (STOP-NIDDM), acarbose reduced the risk of diabetes in those with impaired glucose tolerance by 36% (p=0...
  22. Zeymer U. Cardiovascular benefits of acarbose in impaired glucose tolerance and type 2 diabetes. Int J Cardiol. 2006;107:11-20 pubmed
    ..b>Acarbose, an alpha (alpha)-glucosidase inhibitor, reduces postprandial hyperglycaemia by delaying carbohydrate absorption ..
  23. Penna I, Canella P, Reis R, Silva de Sa M, Ferriani R. Acarbose in obese patients with polycystic ovarian syndrome: a double-blind, randomized, placebo-controlled study. Hum Reprod. 2005;20:2396-401 pubmed
    The present study assessed the effects of low-dose acarbose on obese patients with polycystic ovarian syndrome (PCOS)...
  24. Rosak C, Haupt E, Walter T, Werner J. The effect of combination treatment with acarbose and glibenclamide on postprandial glucose and insulin profiles: additive blood glucose lowering effect and decreased hypoglycaemia. Diabetes Nutr Metab. 2002;15:143-51 pubmed
    This study compared the effects of acarbose plus glibenclamide combination therapy with acarbose or glibenclamide treatment alone on postprandial blood glucose, serum insulin and C-peptide levels, and the tendency to develop hypoglycaemia...
  25. Kato T, Inoue T, Node K. Postprandial endothelial dysfunction in subjects with new-onset type 2 diabetes: an acarbose and nateglinide comparative study. Cardiovasc Diabetol. 2010;9:12 pubmed publisher
    Postprandial hyperglycemia is believed to affect vascular endothelial function. The aim of our study was to compare the effects of acarbose and nateglinide on postprandial endothelial dysfunction.
  26. Abesundara K, Matsui T, Matsumoto K. alpha-Glucosidase inhibitory activity of some Sri Lanka plant extracts, one of which, Cassia auriculata, exerts a strong antihyperglycemic effect in rats comparable to the therapeutic drug acarbose. J Agric Food Chem. 2004;52:2541-5 pubmed
    ..The ED(50) of the extract (4.9 mg/kg) clearly indicated that the antihyperglycemic effect was as potent as that of therapeutic drug, acarbose (ED(50) 3.1 mg/kg).
  27. Zhang M, Yang J, Tao L, Li L, Ma P, Fawcett J. Acarbose bioequivalence: exploration of new pharmacodynamic parameters. AAPS J. 2012;14:345-51 pubmed publisher
    To investigate bioequivalence (BE) testing of an acarbose formulation in healthy Chinese volunteers through the use of recommended and innovative pharmacodynamic (PD) parameters...
  28. Schnell O, Mertes G, Standl E. Acarbose and metabolic control in patients with type 2 diabetes with newly initiated insulin therapy. Diabetes Obes Metab. 2007;9:853-8 pubmed
    This study was designed to investigate the effect of acarbose in patients with type 2 diabetes with newly initiated insulin treatment who had previously been insufficiently controlled with oral antihyperglycaemic agents [haemoglobin A(1c) ..
  29. Vahedi Faridi A, Licht A, Bulut H, Scheffel F, Keller S, Wehmeier U, et al. Crystal structures of the solute receptor GacH of Streptomyces glaucescens in complex with acarbose and an acarbose homolog: comparison with the acarbose-loaded maltose-binding protein of Salmonella typhimurium. J Mol Biol. 2010;397:709-23 pubmed publisher
    ..binding protein (receptor) of the putative oligosaccharide ATP-binding cassette transporter GacFG, encoded in the acarbose biosynthetic gene cluster (gac) from Streptomyces glaucescens GLA.O...
  30. Miyamura M, Schnell O, Yamashita C, Yoshioka T, Matsumoto C, Mori T, et al. Effects of acarbose on the acceleration of postprandial hyperglycemia-induced pathological changes induced by intermittent hypoxia in lean mice. J Pharmacol Sci. 2010;114:32-40 pubmed
    ..changes in the left ventricular (LV) myocardium caused by PPH in lean mice and evaluated the influence of acarbose, an ?-glucosidase inhibitor...
  31. Su J, Wang X, Chen J, Wu G, Jin Y. Glycemic variability in insulin treated type 2 diabetes with well-controlled hemoglobin A1c and its response to further treatment with acarbose. Chin Med J (Engl). 2011;124:144-7 pubmed
    ..5% in duration of twice daily premixed insulin treatment and the effect of further treatment with acarbose. Eighty-six T2DM patients who used premixed insulin analogue (insulin aspart 30) twice daily and had HbA1c < 6...
  32. Inoue I, Shinoda Y, Nakano T, Sassa M, Goto S, Awata T, et al. Acarbose ameliorates atherogenecity of low-density lipoprotein in patients with impaired glucose tolerance. Metabolism. 2006;55:946-52 pubmed
    b>Acarbose, an alpha-glucosidase inhibitor, is administered to control blood glucose levels. The drug also reduces the risk of cardiovascular disease, but the underlying mechanism is still to be elucidated...
  33. Zhang C, Podeschwa M, Altenbach H, Piepersberg W, Wehmeier U. The acarbose-biosynthetic enzyme AcbO from Actinoplanes sp. SE 50/110 is a 2-epi-5-epi-valiolone-7-phosphate 2-epimerase. FEBS Lett. 2003;540:47-52 pubmed
    ..2-epi-5-epi-valiolone is the first precursor of the cyclitol moiety of the alpha-glucosidase inhibitor acarbose in Actinoplanes sp. SE50...
  34. Sonmez A, Yasar L, Savan K, Koc S, Ozcan J, Toklar A, et al. Comparison of the effects of acarbose and metformin use on ovulation rates in clomiphene citrate-resistant polycystic ovary syndrome. Hum Reprod. 2005;20:175-9 pubmed
    The aim of this study was to evaluate the effects of metformin and acarbose on insulin resistance, hormone profiles and ovulation rates in patients with clomiphene citrate-resistant polycystic ovary syndrome (PCOS)...
  35. Watanabe K, Uchino H, Ohmura C, Tanaka Y, Onuma T, Kawamori R. Different effects of two alpha-glucosidase inhibitors, acarbose and voglibose, on serum 1,5-anhydroglucitol (1,5AG) level. J Diabetes Complications. 2004;18:183-6 pubmed
    ..glycemic marker in the control of diabetes; however, treated with alpha-glucosidase inhibitors (alpha-GIs), acarbose (Aca) and voglibose (Vog), it tends to show the discrepancy between serum 1,5AG and related glucose levels...
  36. Hanefeld M, Haffner S, Menschikowski M, Koehler C, Temelkova Kurktschiev T, Wildbrett J, et al. Different effects of acarbose and glibenclamide on proinsulin and insulin profiles in people with Type 2 diabetes. Diabetes Res Clin Pract. 2002;55:221-7 pubmed
    In a double-blind, placebo-controlled study, we compared the effect of acarbose (A) and glibenclamide (G) on post-prandial (pp) and 24-h profiles of proinsulin and insulin...
  37. Josse R, McGuire A, Saal G. A review of the economic evidence for acarbose in the prevention of diabetes and cardiovascular events in individuals with impaired glucose tolerance. Int J Clin Pract. 2006;60:847-55 pubmed
    ..There is an emerging body of cost-effectiveness literature in the management of IGT. For acarbose, an alpha-glucosidase inhibitor, economic analyses have been conducted for Spain, Germany, Sweden and Canada...
  38. McLaughlin C, Thompson A, Greenwood K, Sherington J, Bruce C. Effect of acarbose on milk yield and composition in early-lactation dairy cattle fed a ration to induce subacute ruminal acidosis. J Dairy Sci. 2009;92:4481-8 pubmed publisher
    ..b>Acarbose is commercially available (Glucobay, Bayer, Wuppertal, Germany) and indicated for the control of blood glucose in ..
  39. Sun L, Li M, Wang Y, Zheng Y. Significantly enhanced production of acarbose in fed-batch fermentation with the addition of S-adenosylmethionine. J Microbiol Biotechnol. 2012;22:826-31 pubmed
    b>Acarbose, a pseudo-oligosaccharide, is widely used clinically in therapies for non-insulin-dependent diabetes...
  40. Li C, Begum A, Numao S, Park K, Withers S, Brayer G. Acarbose rearrangement mechanism implied by the kinetic and structural analysis of human pancreatic alpha-amylase in complex with analogues and their elongated counterparts. Biochemistry. 2005;44:3347-57 pubmed
    A mechanistic study of the poorly understood pathway by which the inhibitor acarbose is enzymatically rearranged by human pancreatic alpha-amylase has been conducted by structurally examining the binding modes of the related inhibitors ..
  41. Juretic D, Bernik S, Cop L, Hadzija M, Petlevski R, Lukac Bajalo J. Short-term effect of acarbose on specific intestinal disaccharidase activities and hyperglycaemia in CBA diabetic mice. J Anim Physiol Anim Nutr (Berl). 2003;87:263-8 pubmed
    The purpose of this study was to examine the short-term effects of 75, 100 and 150 mg of acarbose mixed in 100 g standard laboratory chow on specific intestinal disaccharidase activities and on hyperglycaemia in diabetic CBA strain mice ..
  42. Wehmeier U, Piepersberg W. Biotechnology and molecular biology of the alpha-glucosidase inhibitor acarbose. Appl Microbiol Biotechnol. 2004;63:613-25 pubmed
    The alpha-glucosidase inhibitor acarbose, O-[4,6-dideoxy-4[1 s-(1,4,6/5)-4,5,6-trihydroxy-3-hydroxymethyl-2-cyclohexen-1-yl]-amino-alpha-D-glucopyranosyl]-(1-->4)- O-alpha-D-glucopyranosyl-(1-->4)-D-glucopyranose, is produced in ..
  43. van de Laar F, Lucassen P. No evidence for a reduction of myocardial infarctions by acarbose. Eur Heart J. 2004;25:1179; author reply 1179-80 pubmed
  44. Delgado H, Lehmann T, Bobbioni Harsch E, Ybarra J, Golay A. Acarbose improves indirectly both insulin resistance and secretion in obese type 2 diabetic patients. Diabetes Metab. 2002;28:195-200 pubmed
    b>Acarbose is an oral antidiabetic mainly acting on postprandial blood glucose, inhibiting alphaglucosidase. Through this mechanism, it could improve the peripheral insulin sensitivity and/or increase the insulin secretion...
  45. Kim M, Suk J, Kwon M, Chung H, Yoon C, Jun H, et al. Nateglinide and acarbose for postprandial glucose control after optimizing fasting glucose with insulin glargine in patients with type 2 diabetes. Diabetes Res Clin Pract. 2011;92:322-8 pubmed publisher
    ..After fasting glucose was optimized by insulin glargine, nateglinide or acarbose was initiated and then crossed over after second wash out period...
  46. Koyasu M, Ishii H, Watarai M, Takemoto K, Inden Y, Takeshita K, et al. Impact of acarbose on carotid intima-media thickness in patients with newly diagnosed impaired glucose tolerance or mild type 2 diabetes mellitus: A one-year, prospective, randomized, open-label, parallel-group study in Japanese adults with establish. Clin Ther. 2010;32:1610-7 pubmed publisher
    This study examined the effect of acarbose therapy on carotid intima-media thickness (IMT) in patients with established coronary artery disease (CAD) who had been newly diagnosed with impaired glucose tolerance (IGT) or mild type 2 ..
  47. Nyalala J, Luo S, Campbell D, Brown A, Moursi M. The effects of acarbose treatment on intimal hyperplasia in a rat carotid endarterectomy model of diet-induced insulin resistance. Vasc Endovascular Surg. 2010;44:560-7 pubmed publisher
    ..We hypothesize that glucose control using acarbose may attenuate intimal hyperplasia in rat carotid endarterectomy model of diet-induced insulin resistance...
  48. Hucking K, Kostic Z, Pox C, Ritzel R, Holst J, Schmiegel W, et al. alpha-Glucosidase inhibition (acarbose) fails to enhance secretion of glucagon-like peptide 1 (7-36 amide) and to delay gastric emptying in Type 2 diabetic patients. Diabet Med. 2005;22:470-6 pubmed
    b>Acarbose is able to enhance GLP-1 release and delay gastric emptying in normal subjects. The effect of alpha-glucosidase inhibition on GLP-1 has been less evident in Type 2 diabetic patients...
  49. Nakamura K, Yamagishi S, Matsui T, Inoue H. Acarbose, an alpha-glucosidase inhibitor, improves insulin resistance in fructose-fed rats. Drugs Exp Clin Res. 2005;31:155-9 pubmed
    Insulin resistance is one of the determinants of postprandial hyperglycemia. Acarbose is an alpha-glucosidase inhibitor that delays the absorption of carbohydrates from the small intestine, thereby suppressing postprandial hyperglycemia...
  50. Suzuki T, Oba K, Futami S, Suzuki K, Ouchi M, Igari Y, et al. Blood glucose-lowering activity of colestimide in patients with type 2 diabetes and hypercholesterolemia: a case-control study comparing colestimide with acarbose. J Nippon Med Sch. 2006;73:277-84 pubmed
    ..and hypercholesterolemia were more or less randomly assigned to receive either colestimide (17 patients) or acarbose (16 patients)...
  51. Schafer A, Widder J, Eigenthaler M, Bischoff H, Ertl G, Bauersachs J. Increased platelet activation in young Zucker rats with impaired glucose tolerance is improved by acarbose. Thromb Haemost. 2004;92:97-103 pubmed
    ..induced fibrinogen-binding and P-selectin surface-expression, which was prevented by co-administration of acarbose (10 mg.kg-1)...
  52. Gao H, Xie C, Wang H, Lin Y, Hong T. Beneficial metabolic effects of nateglinide versus acarbose in patients with newly-diagnosed type 2 diabetes. Acta Pharmacol Sin. 2007;28:534-9 pubmed
    To investigate the acute and chronic effects of nateglinide versus acarbose on plasma asymmetric dimethylarginine (ADMA) levels and lipid profiles in patients with newly-diagnosed type 2 diabetes...
  53. Goke B. Improved glycemic control and lipid profile in a randomized study of pioglitazone compared with acarbose in patients with type 2 diabetes mellitus. Treat Endocrinol. 2002;1:329-36 pubmed
    To assess the efficacy of pioglitazone treatment in comparison with that of acarbose treatment in patients with type 2 diabetes mellitus...